Turmeric — Could It be a Multi-targeted Herb for Colorectal Cancer Adjuvant Therapy?
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
AbstractTurmeric is a medicinal herb in Asia and as dietary supplement in western countries. Its major active component, curcumin, has good reputation for chemopreventive effects in different cancers. However, poor oral bioavailability of curcumin hinders the wide clinical application of this compound. Our research group made attempts to advance the utilization of the herb turmeric. The presence of lipophilic components (a/b-and aromatic-turmerones) of turmeric was previously shown to facilitate the absorption of curcumin into human intestinal Caco-2 cells. Our recent findings suggested that oral bioavailability of curcumin could be enhanced when curcumin is present in turmeric ethanolic extract. Besides,the anti-proliferative activities of a/b-turmerones in human breast and colon cancer cells, as well as in vitro and in vivo anti-angiogenic activities of aromatic-turmerone have also been demonstrated. Hence, turmeric extract was anticipated to possess anti-tumor effects in colon tumor-bearing mice. In this study, the hypothesis has been verified that turmeric extract plus bevacizumab, a monoclonal antibody approved as first line therapy with chemotherapy in colon cancer, exerted noteworthy anti-tumor activities in human colon tumor-bearing mice. The anti-tumor and life span prolonging efficacies of turmeric extract were comparable to those of the first line hemotherapeutics, 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX). Unlike FOLFOX treatment, the absence of hematologic side effects of turmeric extract treatment was another remarkable finding. In conclusion, our study demonstrated that turmeric ethanolic extract plus bevacizumab possessed potent anti-tumor effects in colon tumor-bearing mice without observable side effect, strongly suggesting the adjuvant use of turmeric in colorectal cancer. Acknowledgement: This work was financially supported by Food and Health Bureau HKSAR, Health and Health
Services Research Fund no. 09100341.
All Author(s) ListYUE Gar Lee Grace, KWOK Hin Fai, LEE Kin Ming, JIANG Lei, GAO Si, CHAN Kar Man, WONG Chun Wai, FUNG Kwok Pui, LEUNG Ping Chung, ZUO Zhong, LAU Bik San Clara
Name of ConferenceJoint Meeting of the GP-TCM Research Association, The TCM Chemistry Specialty Committee and The TCM Pharmaceutical Analysis Specialty Committee of the World Federation of Chinese Medicine Societies
Start Date of Conference12/07/2015
End Date of Conference15/07/2015
Place of ConferenceMons
Country/Region of ConferenceBelgium
Proceedings TitleWorld Journal of Traditional Chinese Medicine
Year2015
Month10
Volume Number1
Issue Number4
Place of PublicationBelgium, Mons
Pages74 - 75
LanguagesEnglish-United Kingdom

Last updated on 2018-04-05 at 12:09